Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals announced that all eight incumbent directors were re-elected during the annual general meeting held on June 7, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.
Detailed results of the vote by proxy for the election of directors are provided below:
Nominee |
Votes For (%) |
Votes Withheld (%) |
||||||
George M. Milne |
80.91 |
|
|
|
19.09 |
|||
Peter Greenleaf |
92.18 |
|
|
|
7.82 |
|||
David R.W. Jayne |
93.00 |
|
|
|
7.00 |
|||
Joseph P. Hagan |
87.15 |
|
|
|
12.85 |
|||
Daniel G. Billen |
95.64 |
|
|
|
4.36 |
|||
R. Hector MacKay-Dunn |
93.27 |
|
|
|
6.73 |
|||
Jill Leversage |
95.05 |
|
|
|
4.95 |
|||
Timothy P. Walbert |
89.56 |
|
|
|
10.44 |
In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005782/en/